These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 32571788)

  • 21. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
    Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with
    Yap TA; Kristeleit R; Michalarea V; Pettitt SJ; Lim JSJ; Carreira S; Roda D; Miller R; Riisnaes R; Miranda S; Figueiredo I; Rodrigues DN; Ward S; Matthews R; Parmar M; Turner A; Tunariu N; Chopra N; Gevensleben H; Turner NC; Ruddle R; Raynaud FI; Decordova S; Swales KE; Finneran L; Hall E; Rugman P; Lindemann JPO; Foxley A; Lord CJ; Banerji U; Plummer R; Basu B; Lopez JS; Drew Y; de Bono JS
    Cancer Discov; 2020 Oct; 10(10):1528-1543. PubMed ID: 32532747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
    Winter C; Nilsson MP; Olsson E; George AM; Chen Y; Kvist A; Törngren T; Vallon-Christersson J; Hegardt C; Häkkinen J; Jönsson G; Grabau D; Malmberg M; Kristoffersson U; Rehn M; Gruvberger-Saal SK; Larsson C; Borg Å; Loman N; Saal LH
    Ann Oncol; 2016 Aug; 27(8):1532-8. PubMed ID: 27194814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
    Fumagalli C; Rappa A; Casadio C; Betella I; Colombo N; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2020 Mar; 73(3):168-171. PubMed ID: 31537627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
    Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
    J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
    Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
    Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis.
    Cheng JM; Canzoniero J; Lee S; Soni S; Mangini N; Santa-Maria CA
    Breast Cancer Res Treat; 2023 Jun; 199(2):389-397. PubMed ID: 37002487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
    Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
    Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
    Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
    PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
    Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
    Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.